← Leaderboards
John Andrew Mackay
Duke University
$5,232,024
Attributed
$7,231,241
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $972.3K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,231,241 · 5
By mechanism
R01$5,866,146 · 2
P30$832,680 · 1
R21$437,643 · 1
F32$94,772 · 1
Top collaborators
- Sarah F Hamm-Alvarez10 shared
Most similar at Duke University
Same institution · by research overlap
- Walter J Koch$36,219,689
- Marc G. Caron$32,189,154
- Farshid Guilak$32,330,672
- L Darryl Quarles$19,109,320
- Thomas M Coffman$20,455,908
Others in their field
Top investigators on “Technology”
- David Heimbrook · Leidos Biomedical Research, Inc.$995,338,451
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$606,570,095
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Richard K. Wilson · Washington University$441,856,657
Research focus
TechnologyEngineeringDesignNovel TherapeuticsProteinsElastinCellsPolypeptidePharmaceutical PreparationsPolymersSiteInnovationFormulationNanomedicineClinically RelevantBiologicalResearch Project GrantsComplexMolecularBindingCellular BiologyPeptidesMediatingChimeric Proteins
Grant awards (26)
Protein-polymer nanomedicine for Sjogren's Syndrome$594,073
R01 · FY2025 · EY
Protein-polymer nanomedicine for Sjogren's Syndrome$118,723
R01 · FY2025 · EY
Protein-polymer nanomedicine for Sjogren's Syndrome$594,073
R01 · FY2024 · EY
Protein-polymer nanomedicine for Sjogren's Syndrome$49,157
R01 · FY2024 · EY
Protein-polymer nanomedicine for Sjogren's Syndrome$592,283
R01 · FY2023 · EY
Ophthalmic Therapeutics Engineering Core$166,536
P30 · FY2022 · EY · contact PI
Protein-polymer nanomedicine for Sjogren's Syndrome$400,125
R01 · FY2021 · EY
Ophthalmic Therapeutics Engineering Core$166,536
P30 · FY2021 · EY · contact PI
Protein-polymer nanomedicine for Sjogren's Syndrome$412,500
R01 · FY2020 · EY
Ophthalmic Therapeutics Engineering Core$166,536
P30 · FY2020 · EY · contact PI
Protein-polymer nanomedicine for Sjogren's Syndrome$412,500
R01 · FY2019 · EY
Intracellular switching using genetically engineered protein microdomains$384,140
R01 · FY2019 · GM · contact PI
Ophthalmic Therapeutics Engineering Core$166,536
P30 · FY2019 · EY · contact PI
Protein-polymer nanomedicine for Sjogren's Syndrome$412,500
R01 · FY2018 · EY
Intracellular switching using genetically engineered protein microdomains$337,298
R01 · FY2018 · GM · contact PI
Ophthalmic Therapeutics Engineering Core$166,536
P30 · FY2018 · EY · contact PI
Intracellular switching using genetically engineered protein microdomains$55,928
R01 · FY2018 · GM · contact PI
Protein-polymer nanomedicine for Sjogren's Syndrome$412,500
R01 · FY2017 · EY
Intracellular switching using genetically engineered protein microdomains$396,317
R01 · FY2017 · GM · contact PI
Intracellular switching using genetically engineered protein microdomains$317,625
R01 · FY2016 · GM · contact PI
Intracellular switching using genetically engineered protein microdomains$59,019
R01 · FY2016 · GM · contact PI
Intracellular switching using genetically engineered protein microdomains$317,385
R01 · FY2015 · GM · contact PI
A rapid, reversible switch for controlling intracellular trafficking$194,643
R21 · FY2011 · EB · contact PI
A rapid, reversible switch for controlling intracellular trafficking$243,000
R21 · FY2010 · EB · contact PI
pH sensitive elastin-like-peptides for tumor targeting$48,796
F32 · FY2007 · CA · contact PI
pH sensitive elastin-like-peptides for tumor targeting$45,976
F32 · FY2006 · CA · contact PI